期刊
BIOMARKERS IN MEDICINE
卷 15, 期 12, 页码 951-963出版社
FUTURE MEDICINE LTD
DOI: 10.2217/bmm-2020-0785
关键词
biomarker; breast invasive ductal carcinoma; diagnosis; miRNA; serum
资金
- Shenzhen High-level Hospital Construction Fund
- Basic Research Project of Peking University Shenzhen Hospital [JCYJ2017001, JCYJ2017004, JCYJ2017005, JCYJ2017006, JCYJ2017007, JCYJ2017012]
- Clinical Research Project of Peking University Shenzhen Hospital [LCYJ2017001]
- Science and Technology Development Fund Project of Shenzhen [JCYJ20180507183102747]
- Shenzhen Health Commission [SZLY2018023]
The study found that a three-miRNA panel constructed by analyzing the expression levels of miRNAs in serum can be used for the diagnosis of breast cancer with high accuracy and sensitivity.
Aim: Breast cancer, especially invasive ductal carcinoma (IDC), is the cause of a great clinical burden. miRNA could be considered as a noninvasive biomarkers for IDC diagnosis. Materials & methods: Two hundred and sixty participants (135 IDC patients and 125 healthy controls) were enrolled in a three-cohort study. The expression of 28 miRNAs in serum were detected with quantitative reverse transcription-PCR. Bioinformatic analysis was used for predicting the target genes of three selected miRNAs. Results: The expression level of seven miRNAs (miR-9-5p, miR-34b-3p, miR-1-3p, miR-146a-5p, miR-20a-5p, miR-34a-5p, miR-125b-5p) was discrepant at the validation cohort. Through statistical test, a three-miRNA panel (miR-9-5p, miR-34b-3p, miR-146a-5p) was significant for IDC diagnosis (AUC = 0.880, sensitivity = 86.25%, specificity = 81.25%). Conclusion: The three-miRNA panel in serum could be used as a noninvasive biomarker in the diagnosis of IDC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据